Biocartis announces that its researchers, in collaboration with researchers at the Wellcome Trust Sanger Institute and at Philips Research, are developing a novel workflow for extraction and amplification & detection of tumor DNA on Biocartis diagnostic platforms. Biocartis retains its full ... more
Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil
Uncovering Mutations Found in Deadly Transmissible Cancer Could Help Conservation Efforts
20-09-2010: Researchers from Illumina, Inc. and the Wellcome Trust Sanger Institute have used Illumina's next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging its population.
The results open the door for new research to pick out those specific mutations that drive the cancer and will lay the foundation for ongoing work to trace the spread of disease and inform the development of preclinical tests, conservation strategies and disease therapies. The announcement is being made by Sanger Institute researcher, Dr. Elizabeth Murchison, at the AMATA 2010 Conference in Hobart, Tasmania, Australia.
The reference Tasmanian devil genome - approximately the same size as the human genome - was sequenced in eight days in one run on Illumina's HiSeq 2000, generating more than 80-fold genome coverage. Two cancer genomes of affected animals from different parts of Tasmania were sequenced at high coverage as well. Sequencing, de novo assembly and analysis of genetic variation of the three genomes has been undertaken jointly by scientists at the Wellcome Trust Sanger Institute and Illumina.
"We're excited about what this project means, not just for the future of this very rare and endangered species and this unusual cancer," said David Bentley, Chief Scientist at Illumina. "It is wonderful to see Illumina's next generation sequencing, with its emphasis on speed, accuracy and genome coverage, opening a world of new possibilities for scientists to get at the root causes and manifestations of disease."
Tasmanian devil facial tumor is almost unique in cancers of the animal kingdom in that it is transmitted by direct transplantation of cancer cells from animal to animal.
"This sequence is invaluable and comes at a crucial time," said Dr. Murchison. "By comparing our draft sequence with samples taken from many hundreds of devils suffering from this cancer, we can begin to look at the spread of the disease, quite literally, by identifying geographical routes and barriers in its transmission. This knowledge could ultimately shape the ongoing conservation efforts in Tasmania.
"It took 10 years to sequence the draft human genome; the devil took just two months using this new technology. We are entering a new era when genome sequencing can be applied to some of our most pressing problems in real time."
The next step will be to sequence many more Tasmanian devil facial tumor samples. By generating profiles of the mutations present in these cancers, the team hopes to improve understanding of the disease and its spread.
Oxford Gene Technology (OGT) has successfully completed processing more than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium (WTCCC), the world’s largest CNV study involving a collaboration of 24 human geneticists. The project analysed DNA samples from ... more
Researchers from Illumina, Inc. and the Wellcome Trust Sanger Institute have used Illumina's next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging ... more
Illumina, Inc. has unveiled a service program to provide high-quality personal genome sequencing for consumers. This is the first service to offer complete coverage of the human genome sequence for under $50,000. The Personal Genome Sequencing Service is performed in Illumina’s recently cer ... more
Illumina and Oxford Nanopore Technologies announced a strategic alliance including a commercialization agreement and equity investment. Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute, and service BASE™ Technology products developed by ... more
Research using data collected from around 4,000 healthy people in the UK has enabled scientists to identify a rare genetic variant that dramatically reduces levels of certain types of lipids in the blood. The study is the first to emerge from the UK10K Project's cohort of samples from the g ... more
Concealed within the vastness of the human genome, (comprised of some 3 billion base pairs), mutations are commonplace. While the majority of these appear to have neutral effect on human health, many others are associated with diseases and disease susceptibility. Reed Cartwright, a research ... more
Researchers have identified an elusive gene responsible for Thrombocytopenia with Absent Radii (TAR), a rare inherited blood and skeletal disorder. As a result, this research is now being transformed into a medical test that allows prenatal diagnosis and genetic counselling in affected fami ... more
- 1Analytik Jena AG Signs Agreement to Acquire Bruker's ICP-MS Business
- 2Schleicher & Schuell has been purchased by Whatman plc
- 3The shadow of a disease
- 4Food analysis and diagnostics are hot topics at analytica China 2014
- 5Analytik Jena Closed Third Quarter Below Expectations
- 6SGS appoints new Chief Financial Officer
- 7SCHOTT Is Now a Stock Corporation
- 8Faster, cheaper tests for sickle cell
- 9Perten Instruments acquires Newport Scientific
- 10Malvern Instruments completes acquisitions